Live Events

CME Requirements By State

Live Events

July
8
Thursday
7:00 PM EDT

GLP-1 RAs

The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

James R. Gavin III, MD, PhD
Healing Our Village, Inc.
Emory University School of Medicine
Atlanta, Georgia

July
22
Thursday
7:00 PM EDT

Gastric and GEJ Cancer

Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

Manish A. Shah, MD, FASCO
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Weill Cornell Medicine/New York-Presbyterian Hospital
New York, New York

August
3
Tuesday
7:00 PM EDT

Venous Thromboembolism (VTE)

Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care & Shared Decision-Making Strategies to Improve Patient Outcomes

Alok A. Khorana, MD, FACP, FASCO
Taussig Cancer Institute
Cleveland Clinic Lerner School of Medicine
Case Western Reserve University
Cleveland, Ohio

Robert D. McBane, II, MD
Mayo Clinic Gonda Vascular Center
Rochester, Minnesota

August
19
Thursday
7:00 PM EDT

B-Cell Cancers

The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

August
26
Thursday
7:00 PM EDT

Psoriasis

Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

April W. Armstrong, MD, MPH
Southern California Clinical and Translational Science Institute (SC CTSI)
Keck School of Medicine
University of Southern California
Los Angeles, California

Kenneth B. Gordon, MD
Medical College of Wisconsin
Milwaukee, Wisconsin

September
1
Wednesday
7:00 PM EDT
September
9
Thursday
6:15 AM CDT

Chronic Lymphocytic Leukemia

Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Jennifer Woyach, MD
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

September
10
Friday
6:30 AM CDT

Myelofibrosis

Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas

September
14
Tuesday
5:00 PM EDT

Non–Small Cell Lung Cancer

Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

Melissa L. Johnson, MD
Sarah Cannon Research Institute
Nashville, Tennessee

September
14
Tuesday
7:00 PM EDT

Multiple Myeloma

Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

September
28
Tuesday
5:00 PM CDT

Immuno-Oncology Biomarkers

Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy

Kurt A. Schalper, MD, PhD
Assistant Professor of Pathology and Medical Oncology
Yale School of Medicine
Director, Translational Immuno-Oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

October
22
Friday
6:00 PM PDT

Eosinophilic Esophagitis

Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina

October
24
Sunday
6:30 PM CDT

Pan Tumor

Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

October
25
Monday
7:00 AM EDT

Immune-Related Adverse Events

Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts

Christopher Baugh, MD, MBA
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

October
26
Tuesday
7:00 AM EDT

Multiple Sclerosis

Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
27
Wednesday
7:00 PM EDT

Multiple Sclerosis

Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

October
29
Friday
12:30 PM EDT
October
29
Friday
6:05 PM EDT

Small Cell Lung Cancer

Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

Jonathan W. Goldman, MD
UCLA Jonsson Comprehensive Cancer Center
Ronald Reagan UCLA Medical Center
UCLA Health - Santa Monica Medical Center
Santa Monica, California

November
2
Tuesday
7:00 PM EDT
November
8
Monday
7:00 PM EST
November
3
Wednesday
12:30 PM EDT

Atopic Dermatitis

Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis

Emma Guttman-Yassky, MD, PhD
Icahn School of Medicine
Mount Sinai Medical Center
New York, New York

November
3
Wednesday
7:00 PM EDT
November
15
Monday
7:00 PM EST

Esophageal/GEJ Cancer

Immunotherapy at the Cutting Edge in Resectable Esophageal/GEJ Cancer: Preparing Thoracic Surgeons and the Broader Multidisciplinary Team to Navigate Changing Standards of Care

Ronan J. Kelly, MD, MBA
Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, Texas
Chief of Oncology, Baylor Scott & White Health System (NTx)
W.W. Caruth Jr. Chair of Immunology at Baylor University Medical Center
Clinical Professor, Texas A&M University College of Medicine
Adjunct Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Professor, Clinical Sciences Division at the Translational Genomics Research Institute
Phoenix, Arizona

Daniela Molena, MD
Director, Esophageal Surgery Program
Memorial Sloan Kettering Cancer Center
New York, New York

November
4
Thursday
9:00 PM EDT

Renal Cell Carcinoma

Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
4
Thursday
7:00 PM EDT
November
22
Monday
7:00 PM EST

NSCLC

Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease

Stephen R. Broderick, MD, MPHS
Johns Hopkins University School of Medicine
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Heather A. Wakelee, MD
Stanford Cancer Center
Stanford, California

November
7
Sunday
5:30 PM EST

Interstitial Lung Disease

Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

November
8
Monday
7:00 PM EST
November
15
Monday
7:00 PM EST

Breast Cancer

Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

November
9
Tuesday
7:00 PM EST

Obesity

Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management

Domenica M. Rubino, MD
Washington Center for Weight Management and Research
Arlington, Virginia

Donna H. Ryan, MD, FTOS
Pennington Biomedical Research Center
Baton Rouge, Louisiana

November
10
Wednesday
7:00 PM EST

Interstitial Lung Disease

Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

November
13
Saturday
6:30 AM EST

Hypertrophic Cardiomyopathy

Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

November
14
Sunday
8:30 AM EST
November
17
Wednesday
7:00 PM EST

HCC/Liver Cancer

Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

Amit Singal, MD, MS
Professor of Medicine
Willis C. Maddrey Chair in Liver Disease
Chief of Hepatology and Medical Director of the Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas

November
14
Sunday
5:00 PM EST

Cardiac irAEs

Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?

Javid Moslehi, MD
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
San Francisco, California

November
16
Tuesday
7:00 PM EST

HIV

Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient

David Malebranche, MD, MPH
Internal Medicine Physician
Atlanta, Georgia

Peter Shalit, MD, PhD
University of Washington
Seattle, Washington

November
20
Saturday
12:45 PM EST

Glioblastoma

A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Tuesday
5:45 PM EST

Bladder Cancer

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

December
1
Wednesday
7:00 AM EST

Prostate Cancer

Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana

December
7
Thursday
8:00 AM EST

Hyperkalemia

Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

December
10
Friday
7:00 AM EST

Follicular Lymphoma

A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

Nathan H. Fowler, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:30 AM EST

Chronic Lymphocytic Leukemia (CLL)

Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
10
Friday
7:30 AM EST

Multiple Myeloma

A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

December
10
Friday
7:30 AM EST

Diffuse Large B-Cell Lymphoma

Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
10
Friday
7:30 AM EST

Acute Myeloid Leukemia

Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:30 AM EST
December
17
Friday
6:30 PM EST

Sickle Cell Disease

The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut

December
14
Tuesday
10:00 AM EST

Eosinophilic Esophagitis

Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy

Chris A. Liacouras, MD
The Children's Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

December
21
Tuesday
7:00 PM EST

Hyperkalemia

Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

January
20
Thursday
6:30 PM PST

Hepatocellular Carcinoma

Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
21
Friday
6:15 PM PST
January
29
Saturday
1:30 PM EST

NSCLC

Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

January
30
Sunday
1:00 PM EST

NSCLC

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

February
9
Wednesday
7:00 PM CST

Stroke

Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California

S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas

February
17
Thursday
7:00 PM PST
February
17
Thursday
7:00 PM PST

Bladder Cancer

Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

February
18
Friday
6:30 PM PST

Prostate Cancer

Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
22
Tuesday
3:05 PM PST
March
8
Tuesday
6:30 PM EST

NSCLC

Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

Pasi A. Jänne, MD, PhD
Lowe Center for Thoracic Oncology
Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

February
23
Wednesday
7:00 PM EST

NSCLC

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

February
24
Thursday
7:00 PM EST

NSCLC

Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
25
Friday
7:00 PM EST
March
7
Monday
7:00 PM EST

Multiple Sclerosis

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland

*Participation in this CME event as an "outside activity"

February
28
Monday
7:00 AM MST

SEVERE ASTHMA

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California

March
10
Thursday
7:15 PM CST

Melanoma

Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
11
Friday
5:15 PM CST

Breast Cancer

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas

March
21
Monday
3:00 PM MST

Ovarian Cancer

When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum

Bradley J. Monk, MD, FACS, FACOG
University of Arizona College of Medicine
Creighton University School of Medicine
GOG-Foundation
Phoenix, Arizona

March
22
Tuesday
6:15 AM PDT

Immuno-Oncology Biomarkers

Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
23
Wednesday
6:15 AM PDT

HER2/HER3/TROP2 Testing/Treatment

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
31
Thursday
7:00 PM EDT

Cancer Screening

Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations

Elizabeth Eaman, MD
Oodle Family Medicine
Renton, Washington
Healthy Transitions, LLC
Montclair, New Jersey
University of Washington
Seattle, Washington

April
7
Thursday
7:00 PM EDT

T2DM and Obesity

Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

Javier Morales, MD, FACP, FACE
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Advanced Internal Medicine Group, PC
East Hills, New York

April
9
Saturday
7:00 PM CDT

Cancer Immunotherapy

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland

April
12
Tuesday
6:00 PM CDT

Ovarian Cancer

Making Sense of The Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy

Thomasina Morris, RPh, MHA, BCOP
Moffitt Cancer Center
Tampa, Florida

April
19
Tuesday
7:00 PM EDT
April
26
Tuesday
7:00 PM EDT
April
28
Thursday
12:15 PM PDT
April
29
Friday
6:00 AM PDT

Chronic Lymphocytic Leukemia

Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
30
Saturday
6:00 PM PDT
May
5
Thursday
7:30 AM EDT

Neurofibromatosis

Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC

May
5
Thursday
12:45 PM EDT

Acute Lymphoblastic Leukemia

Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota

Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia

May
14
Saturday
12:30 PM EDT

NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
14
Saturday
6:00 PM CDT
June
1
Wednesday
7:30 PM EDT

Asthma

The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins

Reynold A. Panettieri, Jr., MD
Robert Wood Johnson Medical School
Rutgers Institute for Translational Medicine and Science
Rutgers University
New Brunswick, New Jersey
University of Pennsylvania

Eileen Wang, MD, MPH
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado

June
2
Thursday
7:00 AM EDT

Multiple Sclerosis

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
3
Friday
7:00 PM CDT

Chronic Lymphocytic Leukemia

Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
3
Friday
7:00 AM EDT

Multiple Sclerosis

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

June
3
Friday
7:00 PM CDT
June
3
Friday
7:00 PM CDT

AML

The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
3
Friday
7:00 PM CDT

Small Cell Lung Cancer

Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Friday
7:00 PM CDT

RCC

Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
6:00 AM CDT

DR/DME

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
12:30 PM EDT

COVID-19

Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

June
4
Saturday
7:00 PM CDT

CAR-T THERAPY

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice

Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
4
Saturday
7:00 PM CDT

HCC/LIVER CANCER

Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

June
4
Saturday
7:00 PM CDT

NSCLC

Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

June
4
Saturday
7:00 PM CDT

MULTIPLE MYELOMA

The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
4
Saturday
7:00 PM CDT

HEAD AND NECK CANCER

The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
5
Sunday
7:00 PM CDT

NSCLC

Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio

June
5
Sunday
7:00 PM CDT

MELANOMA

Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia

June
5
Sunday
7:00 PM CDT

BASAL CELL CARCINOMA

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
5
Sunday
7:00 PM CDT
June
5
Sunday
7:00 PM CDT
June
15
Wednesday
12:00 PM EDT
June
15
Wednesday
7:00 PM EDT
July
1
Friday
13:40 CEST

Gastric Cancer

Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York

July
12
Tuesday
7:00 PM EDT

Diabetic Macular Edema and Diabetic Retinopathy

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

July
12
Tuesday
7:00 PM EDT

Basal Cell Carcinoma

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

July
13
Wednesday
7:00 PM EDT

Nontuberculous Mycobacterial Lung Disease

Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment

Julie V. Philley, MD
University of Texas at Tyler Health Science Center
Tyler, Texas

Kevin Winthrop, MD, MPH
Oregon Health & Science University
Portland, Oregon

July
28
Thursday
12:00 PM EDT
September
1
Thursday
6:00 PM CDT

MANTLE CELL LYMPHOMA

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Nirav Shah, MD, MS
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

September
24
Saturday
6:45 AM CDT

Small Cell Lung Cancer

Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

September
25
Sunday
6:45 AM CDT

NSCLC

Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada

September
26
Monday
6:00 PM CDT

MYELODYSPLASTIC SYNDROMES

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

September
27
Tuesday
12:00 PM EDT

ATOPIC DERMATITIS

Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World

Professor Jacob P. Thyssen
Bispebjerg Hospital
University of Copenhagen
Copenhagen, Denmark

September
28
Wednesday
12:41 PM CDT

ACUTE MYELOID LEUKEMIA

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

September
28
Wednesday
12:41 PM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Deborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

September
29
Thursday
11:50 AM CDT

MULTIPLE MYELOMA

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
29
Thursday
7:00 PM EDT

DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY

A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes

Mark W. Stolar, MD
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

September
30
Friday
12:30 PM EDT

NSCLC

Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings

Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

September
30
Friday
6:45 PM EDT

NSCLC

Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

September
30
Friday
7:00 PM CDT

MULTIPLE MYELOMA

The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity

Praneetha Thulasi, MD
Emory Eye Center
Emory University School of Medicine
Atlanta, Georgia

Jonathan L. Kaufman, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

October
14
Friday
6:30 PM EDT

EOSINOPHILIC ESOPHAGITIS

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Sandeep K. Gupta, MD
Community Health Network
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana

October
17
Monday
6:45 AM CDT

ASTHMA

Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma

Leonard B. Bacharier, MD
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, Tennessee

Monica Kraft, MD
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York

October
23
Sunday
6:30 PM CDT

SOLID TUMORS

Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

November
3
Thursday
7:00 PM CDT

RENAL CELL CARCINOMA

RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
5
Saturday
6:30 AM CDT
November
5
Saturday
1:00 PM EDT

HCC/LIVER CANCER

It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics

Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas

November
5
Saturday
6:00 PM CDT

HEART FAILURE

How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

Javed Butler, MD, MPH, MBA
Baylor Scott and White Research Institute
Dallas, Texas
University of Mississippi
Jackson, Mississippi

November
7
Monday
6:30 AM CST

HYPERLIPIDEMIA

Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies

Peter H. Jones, MD, MNLA
Center for Cardiometabolic Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, Texas

R. Scott Wright, MD
Mayo Clinic
Rochester, Minnesota

November
12
Saturday
8:30 PM EST

SEVERE ASTHMA

Leveling the Playing Field for All Patients With Severe Asthma: Directing New Treatment Approaches at the Airway Epithelium

Juan Carlos Cardet, MD
University of South Florida
Tampa, Florida

Geoffrey L. Chupp, MD
Yale School of Medicine
Yale Center for Asthma and Airway Disease
Yale New Haven Hospital
New Haven, Connecticut

November
16
Wednesday
12:45 CET

BREAST CANCER

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

Professor Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
Bart's Cancer Institute, Queen Mary University of London
London, England, United Kingdom

November
17
Thursday
5:30 PM EST

GLIOBLASTOMA

Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

November
28
Monday
1:30 PM CST

ALZHEIMER'S DISEASE

Revealing the Neuropathology of Alzheimer’s Disease Through Novel Fluid and Imaging Biomarkers: Ushering in a Precision Era of Diagnosis and Treatment

Val J. Lowe, MD
Mayo Clinic
Rochester, Minnesota

Jonathan E. McConathy, MD, PhD
University of Alabama at Birmingham
Heersink School of Medicine
Birmingham, Alabama

November
29
Tuesday
7:00 PM EST

DESMOID TUMORS

On the Cusp of Change: Modernizing the Treatment of Desmoid Tumors With Novel Gamma Secretase Inhibitors

Bernd Kasper, MD, PhD
University of Heidelberg
Mannheim Cancer Center (MCC)
Mannheim, Germany

November
30
Wednesday
7:00 AM PST

BLADDER CANCER

Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Center
Seattle, Washington

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina

November
30
Wednesday
12:00 PM PST

PROSTATE CANCER

Case by Case: Maximizing Personalized Approaches to Prostate Cancer

Rana R. McKay, MD
UC San Diego Moores Cancer Center
University of California San Diego
La Jolla, California

Alicia K. Morgans, MD, MPH
Dana-Farber Cancer Center
Boston, Massachusetts

December
6
Tuesday
7:15 PM CST

BREAST CANCER

Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer

Erika Hamilton, MD
Sarah Cannon Research
Institute/Tennessee Oncology
Nashville, Tennessee

December
7
Wednesday
11:30 AM PST
December
9
Friday
7:30 AM CST

LYMPHOMA

The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care

Jason Westin, MD, MS, FACP
The University of Texas
MD Anderson Cancer Center
Houston, Texas

December
9
Friday
7:30 AM CST

COLD AGGLUTININ DISEASE (CAD)

Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs

Sigbjørn Berentsen, MD, PhD
Haugesund Hospital
Haugesund, Norway

Ilene C. Weitz, MD
Keck-USC School of Medicine
Los Angeles, California

December
9
Friday
7:30 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
9
Friday
7:30 AM CST

DIFFUSE LARGE B-CELL LYMPHOMA

Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
9
Friday
7:30 AM CST

MULTIPLE MYELOMA

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts

December
9
Friday
7:30 AM CST

LEUKEMIA

The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care

Vivian G. Oehler, MD
Fred Hutchinson Cancer Center
University of Washington
Seattle, Washington

December
9
Friday
7:30 AM CST

LYMPHOMA

Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

December
9
Friday
7:30 AM CST

ACUTE MYELOID LEUKEMIA

Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

December
9
Friday
11:00 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
9
Friday
3:30 PM CST

MYELODYSPLASTIC SYNDROMES

The Future Is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

January
17
Tuesday
1:00 PM EST

COVID-19

Improving Outcomes for Hospitalized Patients With COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice

Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP
Royal Free Hospital
London, England, United Kingdom

January
19
Thursday
6:00 PM PST

GI MALIGNANCIES

Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations

Vivek Subbiah, MD
The University of Texas MD Anderson Cancer Center
MD Anderson Cancer Center Network
Houston, Texas

January
19
Thursday
6:00 PM PST

HCC

The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York

January
20
Friday
6:30 PM EST

CHRONIC LYMPHOCYTIC LEUKEMIA

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

January
20
Friday
5:45 PM PST

BILIARY CANCER

Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents

Rachna T. Shroff, MD, MS
University of Arizona Cancer Center (UACC)
UA College of Medicine – Tucson (UA COM-T)
Tucson, Arizona

January
21
Saturday
12:10 PM PST

NSCLC

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

January
22
Sunday
12:40 PM PST

NSCLC

EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know

Catherine Shu, MD
Columbia University Medical Center
New York, New York

January
26
Thursday
7:00 PM EST

PSORIASIS

Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic

April W. Armstrong, MD, MPH
Keck School of Medicine
University of Southern California
Los Angeles, California

January
31
Tuesday
1:00 PM EST

COVID-19

Improving Outcomes for Hospitalized Patients With COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice

Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP
Royal Free Hospital
London, England, United Kingdom

February
2
Thursday
7:00 PM EST

ALZHEIMER'S DISEASE

Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease

Marwan Sabbagh, MD, FAAN
Professor of Neurology, Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
Research Professor
University of Arizona College of Medicine-Phoenix
Clinical Professor of Neurology
Creighton University
Phoenix, Arizona

February
15
Wednesday
7:00 PM EST

HCC

Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease

Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Mark Yarchoan, MD
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

February
16
Thursday
7:00 PM PST

RCC

Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic Strategies

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

February
16
Thursday
7:00 PM PST

BLADDER CANCER

Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

Matthew I. Milowsky, MD, FASCO
University of North Carolina at Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

February
17
Friday
6:30 PM PST

PROSTATE CANCER

Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care

Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

February
22
Wednesday
3:45 PM PST
February
23
Thursday
6:30 PM PST

NSCLC

Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada

February
24
Friday
6:30 PM PST

NSCLC

Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

March
2
Thursday
7:00 PM EST
March
16
Thursday
7:00 PM EDT
March
5
Sunday
6:45 AM CST

HYPERTROPHIC CARDIOMYOPATHY (HCM)

Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment

Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

March
13
Monday
6:15 AM CDT

BREAST CANCER

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment

Stuart J. Schnitt, MD
Dana-Farber/Brigham and Women’s Cancer Center
Harvard Medical School
Boston, Massachusetts

Paolo Tarantino, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

March
13
Monday
6:45 AM CDT

MYELODYSPLASTIC SYNDROMES

Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment

Rami Komrokji, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Cecilia CS Yeung, MD
Fred Hutch Cancer Center
University of Washington
Fred Hutch Clinical Testing Laboratories
Seattle, Washington

March
14
Tuesday
6:15 AM CDT

AML

The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Joseph D. Khoury, MD, FCAP
University of Nebraska Medical Center
Omaha, Nebraska

March
14
Tuesday
6:45 AM CDT

IMMUNO-ONCOLOGY BIOMARKERS

Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment

Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

March
23
Thursday
7:30 PM EDT

MELANOMA

Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
23
Thursday
7:30 PM EDT

BREAST CANCER

Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer

Laura S. Dominici, MD, FACS
Harvard Medical School
Brigham and Women's Faulkner Hospital
Dana-Farber Brigham Cancer Center
Brigham and Women's Hospital
Boston, Massachusetts

March
25
Saturday
11:45 AM EDT

ENDOMETRIAL CANCER

Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care

David M. O'Malley, MD
The James Cancer Hospital and Solove Research Institute
The Ohio State University College of Medicine
Columbus, Ohio

March
30
Thursday
7:00 PM EDT

MELANOMA

Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
31
Friday
7:00 AM MST

CHRONIC LYMPHOCYTIC LEUKEMIA

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Emily K. Dotson, PharmD, BCOP
The James Cancer Hospital
Columbus, Ohio

April
13
Thursday
7:00 PM EDT

MULTIPLE MYELOMA

Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Emory University School of Medicine
Winship Cancer Institute of Emory University
Atlanta, Georgia

Zahra Mahmoudjafari, PharmD, MBA, BCOP
The University of Kansas Cancer Center
Kansas City, Kansas

April
16
Sunday
12:00 PM HAST

NON-CYSTIC FIBROSIS BRONCHIECTASIS

Improving Time to Diagnosis of Non–Cystic Fibrosis Bronchiectasis: The Importance of the Radiologist in Fulfilling Unmet Needs of Patients

Charles L. Daley, MD
National Jewish Health
Denver, Colorado

Mary M. Salvatore, MD
Columbia University Irving Medical Center
New York, New York

April
18
Tuesday
7:00 PM EDT

IRRITABLE BOWEL SYNDROME

Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
McGovern Medical School
University of Texas Health Science Center at Houston
Houston, Texas

Kimberly Kearns, APRN, ANP-BC
DULY Health and Care
Hoffman Estates, Illinois

April
26
Wednesday
6:00 PM CDT

GYNECOLOGIC CANCERS

Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

Kimberly Halla, MSN, FNP-C
CaroMont Regional Medical Center
Gastonia, North Carolina

April
26
Wednesday
6:30 PM PDT

ALZHEIMER'S DISEASE

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Anna Chodos, MD, MPH
Zuckerberg San Francisco General Hospital
University of California
San Francisco, California

Ian Neel, MD
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California

April
27
Thursday
6:00 AM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Leading Change, Leading Advances in CLL Care: Guidance on Delivering Modern Targeted and Cellular Therapeutics

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
University of California San Francisco
San Francisco, California

April
27
Thursday
7:45 PM CDT

MULTIPLE MYELOMA

Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Case Comprehensive Cancer Center
Cleveland Ohio

April
28
Friday
6:00 PM CDT

NSCLC

Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Yale School of Nursing
Yale Comprehensive Cancer Center & Smilow Cancer Center
New Haven, Connecticut

April
29
Saturday
6:00 AM CDT

BLADDER CANCER

Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care

Brenda Martone, MSN, ANP-BC, AOCNP
Northwestern Medicine
Chicago, Illinois

May
6
Saturday
12:00 PM PDT

NSCLC

Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
8
Monday
12:15 PM PDT

NSCLC

Bringing Precision Lung Cancer Care to the Perioperative Space: How to Maximize the Impact of EGFR-Targeted Therapy in Resectable NSCLC

Catherine Shu, MD
Columbia University Medical Center
New York, New York

Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

May
8
Monday
6:30 PM CDT

IBD

Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis

Miguel Regueiro, MD
Digestive Disease and Surgery Institute
Cleveland Clinic
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio

May
10
Wednesday
11:00 AM CDT

NEUROFIBROMATOSIS TYPE 1

The Bedrock of Personalized NF1 Care: Fundamentals of Managing NF1-Associated PNs and Other Tumors With Innovative Targeted Therapy

Laura Klesse, MD, PhD
UT Southwestern Medical Center
Dallas, Texas

Carlos G. Romo, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

May
11
Thursday
12:30 PM CDT

ACUTE LYMPHOBLASTIC LEUKEMIA

Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy

Luke Maese, DO
University of Utah - Huntsman Cancer Institute
Primary Children's Hospital
Salt Lake City, Utah

Rachel Rau, MD
Texas Children's Cancer and Hematology Center
Baylor College of Medicine
Houston, Texas

June
1
Thursday
7:00 AM MDT

MULTIPLE SCLEROSIS

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Amit Bar-Or, MD, FRCPC
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
2
Friday
7:30 AM EDT

HYPERLIPIDEMIA

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

P. Barton Duell, MD
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

June
2
Friday
7:00 PM CDT

IMMUNE THROMBOCYTOPENIA

New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes

David J. Kuter, MD, DPhil
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Cindy Neunert, MD, MSCS
Columbia University Irving Medical Center
New York, New York

June
2
Friday
7:00 PM CDT

HEAD AND NECK CANCER

Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care

Barbara Burtness, MD
Yale Cancer Center
New Haven, Connecticut

June
2
Friday
7:00 PM CDT

HCC/LIVER CANCER

Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York

June
2
Friday
7:00 PM CDT

RENAL CELL CARCINOMA

Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

June
2
Friday
7:00 PM CDT

CLL

Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Saturday
7:00 AM MDT

MULTIPLE SCLEROSIS

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Jiwon Oh, MD, PhD, FRCPC
St. Michael’s Hospital
University of Toronto
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

June
3
Saturday
7:00 PM CDT

NSCLC

Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

June
3
Saturday
7:00 PM CDT

ENDOMETRIAL CANCER

Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

David M. O'Malley, MD
The James Cancer Hospital and Solove Research Institute
The Ohio State University College of Medicine
Columbus, Ohio

June
3
Saturday
7:00 PM CDT

MULTIPLE MYELOMA

The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms

Robert Z. Orlowski, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
3
Saturday
7:00 PM CDT

ACUTE MYELOID LEUKEMIA

Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
3
Saturday
7:00 PM CDT

MELANOMA

Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options

Jason J. Luke, MD, FACP
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, Pennsylvania

June
4
Sunday
6:00 PM CDT

MYELOFIBROSIS

Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms & Emerging Therapeutics

Ruben A. Mesa, MD, FACP
Enterprise Cancer Service Line
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Atrium Health
Wake Forest University School of Medicine
Winston-Salem, North Carolina

June
4
Sunday
7:00 PM CDT

SCLC

Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

June
4
Sunday
7:00 PM CDT

MYELODYSPLASTIC SYNDROMES

The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
6
Tuesday
12:45 PM PDT

COVID-19

What’s New, and What’s Next? Customizing COVID-19 Prevention Approaches in Transplant Patients to Increase Uptake, Access, and Efficacy

Shmuel Shoham, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

Ghady Haidar, MD
University of Pittsburgh and UPMC
Pittsburgh, Pennsylvania

June
8
Thursday
7:00 PM EDT

GI CANCERS

Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care

Elena Elimova, MD, M.Sc., FRcPC
University of Toronto
Princess Margaret Cancer Centre
Toronto, Ontario, Canada

June
22
Thursday
12:00 PM EDT

ACUTE MYELOID LEUKEMIA

“Intensity” With Efficacy in Acute Myeloid Leukemia (AML): Developing Modern, Intensive Upfront Platforms for Challenging Disease Presentations

Prof. Thomas Cluzeau, MD, PhD
Nice University Hospital / Cote d’Azur University / Mediterranean Center of molecular Medecine, INSERM U1065
Nice, France

June
24
Saturday
11:45 AM EDT

HEMOPHILIA

Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products

Steven W. Pipe, MD
University of Michigan
Ann Arbor, Michigan

Maria Elisa Mancuso, MD, PhD
Center for Thrombosis and Hemorrhagic Diseases
IRCCS Humanitas Research Hospital, Rozzano
Humanitas University, Pieve Emanuele
Milan, Italy

June
25
Sunday
6:45 AM CDT

ALZHEIMER’S DISEASE

Navigating the New Era of Molecularly-Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

Gil Rabinovici, MD
UCSF Alzheimer’s Disease Research Center
University of California, San Francisco
San Francisco, California

Ilya M. Nasrallah, MD, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

July
13
Thursday
7:00 PM EDT

PEDIATRIC GROWTH HORMONE DEFICIENCY

Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies

Bradley S. Miller, MD, PhD
University of Minnesota Medical School
M Health Fairview Masonic Children's Hospital
Minneapolis, Minnesota

July
17
Monday
13:00 CEST

ALZHEIMER’S DISEASE

Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA)

Stephen P. Salloway, MD, MS
Alpert Medical School of Brown University
Brown Center for Alzheimer’s Disease Research
Providence, Rhode Island

August
24
Thursday
7:00 PM EDT

ATOPIC DERMATITIS

Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Portland, Oregon

Peter A. Lio, MD
Northwestern University Feinberg School of Medicine
Chicago Integrative Eczema Center
Chicago, Illinois

August
29
Tuesday
7:00 PM EDT

HEMOPHILIA

Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A

Stacy E. Croteau, MD, MMS
Boston Children’s Hospital
Boston Hemophilia Center
Harvard Medical School
Boston, Massachusetts

Steven W. Pipe, MD
University of Michigan
Ann Arbor, Michigan

September
6
Wednesday
11:51 AM CDT

MYELODYSPLASTIC SYNDROME

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amy E. DeZern, MD, MHS
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

September
6
Wednesday
11:51 AM CDT

MULTIPLE MYELOMA

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

September
6
Wednesday
7:35 PM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations

William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Nicole Lamanna, MD
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

September
7
Thursday
6:45 AM CDT

ACUTE MYELOID LEUKEMIA

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Gail J. Roboz, MD
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

September
9
Saturday
12:00 SGT

NSCLC

A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

September
10
Sunday
6:00 AM EDT

RETT SYNDROME

The Changing Future for Patients With Rett Syndrome and Their Families: Early Diagnosis and Emerging Therapies to Reduce the Burdens of Disease

Jeffrey L. Neul, MD, PhD
Vanderbilt Kennedy Center
Vanderbilt University Medical Center
Nashville, Tennessee

Alan K. Percy, MD
University of Alabama
Birmingham, Alabama

September
12
Tuesday
13:15 SGT
September
29
Friday
6:45 AM CDT

MYELODYSPLASTIC SYNDROMES

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

Michael R. Savona, MD
Vanderbilt University School of Medicine
Nashville, Tennessee

Andrew M. Brunner, MD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

October
1
Sunday
6:30 PM PDT

SOLID TUMORS

Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond

Erik P. Sulman, MD, PhD
Laura and Isaac Perlmutter Cancer Center
Vilcek Institute of Graduate Biomedical Sciences/NYU Grossman School of Medicine
NYU Langone Health
New York, New York

October
2
Monday
11:30 CEST

DIABETES

Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care

Hiddo J.L. Heerspink, PhD, PharmD
University Medical Center Groningen
Groningen, Netherlands

Prof. Dr. med Christoph Wanner
University Hospital of Würzburg
Würzburg, Germany

October
5
Thursday
7:30 PM PDT

EOSINOPHILIC ESOPHAGITIS

Living With Eosinophilic Esophagitis: Recognizing the Burden on Patients and Integrating Targeted Therapy to Improve Outcomes

Seema S. Aceves, MD, PhD
University of California
Eosinophilic Gastrointestinal Disorders Clinic
Rady Children’s Hospital
San Diego, California

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

October
7
Saturday
7:30 AM EDT

DEPRESSION

Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
The Hamilton Group Behavioral Health LLC
Las Vegas, Nevada

Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Rasmussen University
Bloomington, Minnesota

October
7
Saturday
12:55 PM EDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

October
8
Sunday
7:00 AM EDT

HYPERTROPHIC CARDIOMYOPATHY

Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond

Milind Desai, MD, MBA
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland, Ohio

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

October
9
Monday
6:30 AM EDT

ANTICOAGULATION REVERSAL

Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding

Truman J. Milling Jr., MD, FACEP
Seton Dell Medical School Stroke Institute
Austin, Texas

October
12
Thursday
7:00 PM EDT

DEPRESSION

Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
The Hamilton Group Behavioral Health LLC
Las Vegas, Nevada

Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Rasmussen University
Bloomington, Minnesota

October
21
Saturday
7:00 PM EDT

Rett Syndrome

Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management

Eric Marsh, MD, PhD
Intellectual and Developmental Disabilities Research Center
Children’s Hospital of Philadelphia
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

October
25
Wednesday
12:00 PM EDT

MANTLE CELL LYMPHOMA

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

Nirav Shah, MD, MS
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

November
1
Wednesday
12:00 PM MST
November
16
Thursday
7:00 PM EST

AMYOTROPHIC LATERAL SCLEROSIS

Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options

James D. Berry, MD, MPH
MGH Neurological Clinical Research Institute (NCRI)
Sean M. Healey and AMG Center for ALS
Massachusetts General Hospital
Boston, Massachusetts

Sabrina Paganoni, MD, PhD
Massachusetts General Hospital
Healey & AMG Center for ALS at Mass General
Spaulding Rehabilitation Hospital
Harvard Medical School
Boston, Massachusetts

November
9
Thursday
2:30 PM EDT

SOLID TUMORS

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Yale Comprehensive Cancer Center & Smilow Cancer Center
Yale School of Nursing
New Haven, Connecticut

November
10
Friday
7:15 PM CST

RENAL CELL CARCINOMA

Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
11
Saturday
8:15 PM PST

SEVERE ASTHMA

Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

Jonathan Corren, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

Mario Castro, MD
Frontiers Clinical and Translational Science Institute at the University of Kansas
University of Kansas School of Medicine
Kansas City, Kansas

November
12
Sunday
6:30 PM EST

THROMBOSIS

Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

Roxana Mehran, MD
The Center for Interventional Cardiovascular Research and Clinical Trials
Center for Women’s Heart Health at Mount Sinai
New York, New York

Jeffrey Weitz, MD, FRCPC, FRSC, FACP
McMaster University
Thrombosis & Atherosclerosis Research Institute
Hamilton, Ontario, Canada

November
16
Thursday
5:30 PM PST

GLIOBLASTOMA

Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches

Steven Brem, MD
Hospital of the University of Pennsylvania
Penn Brain Tumor Center
Abramson Cancer Center
Philadelphia, Pennsylvania

November
13
Monday
12:00 PM EST
November
16
Thursday
8:00 PM EST

RETINAL VEIN OCCLUSION

Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein Occlusions

Robert M. Hughes, DO
University Hospitals, Cleveland Medical Center
Cleveland, Ohio

Christina Y. Weng, MD, MBA
Baylor College of Medicine
Houston, Texas

November
28
Tuesday
12:00 PM EST

EOSINOPHILIC ESOPHAGITIS

Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

PD Dr. med. Luc Biedermann
University Hospital Zurich
Zurich, Switzerland

Jonathan Spergel, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

November
29
Wednesday
7:00 AM EST

BLADDER CANCER

Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina

November
30
Thursday
6:15 AM CST
December
1
Friday
11:45 AM EST

PROSTATE CANCER

Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina

December
3
Sunday
7:00 AM CST

NSCLC

Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

December
3
Sunday
7:00 AM CST

SCLC

Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

December
5
Tuesday
7:15 PM CST

Metastatic HER2-Positive Breast Cancer

Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer

Sara A Hurvitz, MD, FACP
University of Washington Medicine
Fred Hutchinson Cancer Center
Seattle, Washington

December
6
Wednesday
7:15 PM CST
December
8
Friday
7:30 AM PST

MULTIPLE MYELOMA

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts

December
8
Friday
7:30 AM PST

MYELODYSPLASTIC SYNDROMES

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and Treatment

María Díez Campelo, MD, PhD
University Hospital of Salamanca, IBSAL
Salamanca, Spain

December
8
Friday
11:30 AM PST

CHRONIC LYMPHOCYTIC LEUKEMIA

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
8
Friday
3:30 PM PST
December
8
Friday
3:30 PM PST

ACUTE MYELOID LEUKEMIA

Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

Sergio A. Giralt, MD, FACP
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York

Selina Luger, MD, FRCPC
Perelman School of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

December
13
Wednesday
7:00 PM EST

HEMOPHILIA

The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor Therapy

Amy Shapiro, MD
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Prof Pratima Chowdary, MD, FRCPATH
University College London
KD Comprehensive Care Haemophilia Centre
Royal Free London NHS Foundation Trust
London, United Kingdom

January
10
Wednesday
12:00 PM EST

BREAST CANCER

Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in HR+, HER2- Metastatic Breast Cancer

Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

January
17
Wednesday
12:00 PM EST

CHRONIC LYMPHOCYTIC LEUKEMIA

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Meghan C. Thompson, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Catherine C. Coombs, MD
University of California, Irvine
Orange, California

January
18
Thursday
12:00 PM EST
January
18
Thursday
5:30 PM PST

HCC

Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

Ghassan Abou-Alfa, MD, MBA
New York, New York
Memorial Sloan Kettering Cancer Center
Weill Cornell College at Cornell University
Trinity College Dublin

January
18
Thursday
5:30 PM PST
January
25
Thursday
6:15 PM PST

RCC

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

January
25
Thursday
6:15 PM PST

PROSTATE CANCER

Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

January
26
Friday
7:00 PM PST

BLADDER CANCER

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

Matthew D. Galsky, MD
Icahn School of Medicine at Mount Sinai
Tisch Cancer Institute
New York, New York

January
27
Saturday
7:45 AM PST

HCC

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist—Oncologist Collaboration Across the Disease Continuum

Lipika Goyal, MD, MPhil
Stanford School of Medicine
Palo Alto, California

Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois

January
28
Sunday
5:55 AM CST

NSCLC

A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

Jessica Donington, MD
The University of Chicago Medicine
Chicago, Illinois

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

January
28
Sunday
11:40 AM CST

NSCLC

Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC

Brendon M. Stiles, MD
Montefiore Einstein Comprehensive Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York

February
7
Wednesday
7:00 PM EST
February
15
Thursday
12:00 PM EST

ALZHEIMER'S DISEASE

Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools & Strategies for Radiology & Neuroradiology Specialists

Jerome A. Barakos, MD
California Pacific Medical Center
San Francisco, California

Tammie L.S. Benzinger, MD, PhD
Mallinckrodt Institute of Radiology
Washington University School of Medicine
St. Louis, Missouri

February
21
Wednesday
3:45 PM PST
February
23
Friday
7:00 AM PST

NSCLC

The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

Sandip Patel, MD
University of California San Diego
Sanford Stem Cell Clinical Center
La Jolla, California

February
23
Friday
5:40 PM PST

NSCLC

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

February
24
Saturday
7:00 AM PST

SCLC

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Taofeek K. Owonikoko, MD, PhD
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland School of Medicine
University of Maryland, Baltimore
University of Maryland Medical Center
Baltimore, Maryland

March
8
Friday
7:00 PM PST

CHRONIC SPONTANEOUS URTICARIA

Advancing Patient Care in Chronic Spontaneous Urticaria: Reshaping the Future With Targeted Biologic Therapies

April W. Armstrong, MD, MPH
University of California, Los Angeles (UCLA)
Los Angeles, California

Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI
Specialist, Clinical Immunology and Allergy and Internal Medicine
Toronto, Ontario, Canada

March
17
Sunday
7:30 AM PDT

GYNECOLOGIC CANCERS

Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

Bradley J. Monk, MD, FACS, FACOG
Florida Cancer Specialists and Research Institute
West Palm Beach, Florida

March
18
Monday
12:30 PM PDT

ENDOMETRIAL/OVARIAN CANCER

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Kathleen N. Moore, MD, MS
Stephenson Cancer Center at the University of Oklahoma HSC
Oklahoma City, Oklahoma

March
19
Tuesday
12:00 PM EDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations

Prof. Dr. med. Stephan Stilgenbauer
Comprehensive Cancer Center Ulm
Ulm University
Ulm, Germany

March
21
Thursday
7:30 PM EDT

MELANOMA

New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
21
Thursday
7:30 PM EDT

BREAST CANCER

Unraveling the Complex Choices in Early Breast Cancer: A Roadmap to Informed Multidisciplinary Decisions About Assessment and Treatment

Laura S. Dominici, MD, FACS
Harvard Medical School
Brigham and Women's Faulkner Hospital
Dana-Farber Brigham Cancer Center
Brigham and Women's Hospital
Boston, Massachusetts

March
27
Wednesday
12:10 PM MDT

HCC

The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Continuum

Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Lipika Goyal, MD, MPhil
Stanford School of Medicine
Palo Alto, California

April
3
Wednesday
7:00 AM EDT

MULTIPLE MYELOMA

Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Emory University School of Medicine
Winship Cancer Institute of Emory University
Atlanta, Georgia

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
The University of Kansas Cancer Center
Kansas City, Kansas

April
3
Wednesday
11:30 AM PDT

NEUROFIBROMATOSIS TYPE 1

Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 PNs and Other Tumors

Carlos G. Romo, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

Aimee Sato, MD
Seattle Children’s
UW Medicine
Seattle, Washington

April
6
Saturday
6:15 PM EDT

CRSwNP

Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

Joseph K. Han, MD
Eastern Virginia Medical School
Norfolk, Virginia

Seth J. Isaacs, MD
TriHealth
Good Samaritan Hospital
Cincinnati, Ohio

April
17
Wednesday
12:00 PM CDT

HCM

Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy

Milind Desai, MD, MBA, FACC, FAHA, FESC
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland Clinic
Cleveland, Ohio

Andrew Willeford, PharmD, PhD, BCCP
UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
La Jolla, California

April
25
Thursday
6:00 AM EDT

NSCLC

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Yale Comprehensive Cancer Center & Smilow Cancer Center
Yale School of Nursing
New Haven, Connecticut

Beth Sandy, MSN, CRNP, FAPO
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

April
26
Friday
6:00 AM EDT

MULTIPLE MYELOMA

Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Case Comprehensive Cancer Center
Cleveland, Ohio

May
3
Friday
8:30 AM CDT

BLADDER CANCER

Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
Myrtle Beach, South Carolina

May
7
Tuesday
7:00 PM EDT

NSCLC

Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches

Jessica Donington, MD
The University of Chicago Medicine
Chicago, Illinois

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
8
Wednesday
7:00 PM EDT
May
16
Thursday
12:00 PM EDT

ALZHEIMER’S DISEASE

Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows

Jonathan E. McConathy, MD, PhD
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Gil Rabinovici, MD
UCSF Alzheimer’s Disease Research Center
University of California, San Francisco
San Francisco, California

May
19
Sunday
6:30 PM EDT

METABOLIC DYSFUNCTION–ASSOCIATED STEATOHEPATITIS

Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

Rohit Loomba, MD, MHSc
MASLD Research Center
University of California at San Diego
La Jolla, California

May
19
Sunday
7 p.m. PT

NCFBE

Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options

Doreen J. Addrizzo-Harris, MD
NYU School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
Newport Beach, California

May
22
Wednesday
12:00 PM EDT

BREAST CANCER

Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

Professor Stephen Johnston, MA, PhD
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
Chelsea, London, United Kingdom

May
29
Wednesday
7:00 PM EDT

ALZHEIMER'S DISEASE

Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment

Val J. Lowe, MD
Mayo Clinic
Rochester, Minnesota

Cyrus A. Raji, MD, PhD
Washington University
St. Louis, Missouri

May
31
Friday
7:00 AM CDT

MULTIPLE SCLEROSIS

Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS

Amit Bar-Or, MD, FRCPC
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Jiwon Oh, MD, PhD, FRCPC
St. Michael’s Hospital
University of Toronto
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

May
31
Friday
7:00 PM CDT

HER2+ GI MALIGNANCIES

Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

Yelena Y. Janjigian*, MD
Memorial Sloan Kettering Cancer Center
New York, New York

* This activity was developed with Yelena Y. Janjigian, MD, and is not affiliated in any capacity with Memorial Sloan Kettering Cancer Center.

May
31
Friday
7:00 PM CDT

BREAST CANCER

Advancing Novel Therapies for HER2-Positive, HER2-Low, and HR-Positive Breast Cancer: Solutions for Selecting and Sequencing Therapeutic Approaches

Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
New York, New York

June
1
Saturday
7:00 PM CDT

ADCs IN BLADDER CANCER

Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care

Petros Grivas, MD, PhD
University of Washington School of Medicine
Fred Hutchinson Cancer Center
Seattle, Washington

June
1
Saturday
7:00 PM CDT
December
10
Friday
7:30 AM EST

CAR-T Therapy

Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

December
10
Friday
11:30 AM EST

Chronic Lymphocytic Leukemia

Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

September
10
Friday
7:15 PM MDT

Hypertrophic Cardiomyopathy

Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

Aurora, Colorado

Daniel Jacoby, MD
Yale New Haven Health
Yale School of Medicine
New Haven, Connecticut

October
22
Friday
5:30 PM PDT

Eosinophilic Esophagitis

Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Las Vegas, NV

Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina

October
24
Sunday
6:00 PM CDT

Pan Tumor

Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Chicago, IL

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

October
25
Monday
6:30 AM EDT

Immune-Related Adverse Events

Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

Boston, MA

Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts

October
26
Tuesday
6:30 AM EDT

Multiple Sclerosis

Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Orlando, Florida

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
27
Wednesday
6:30 PM EDT

Multiple Sclerosis

Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Orlando, Florida

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

October
29
Friday
12:15 PM EDT

NSCLC

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Boston, MA

Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

November
4
Thursday
8:30 PM EDT

Renal Cell Carcinoma

Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Austin, TX

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
20
Saturday
12:15 PM EST

Glioblastoma

A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

Boston, MA

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Tuesday
5:30 PM EST

Bladder Cancer

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Orlando, FL

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

December
1
Wednesday
6:30 AM EST

Prostate Cancer

Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

Orlando, FL

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana

December
10
Friday
7:00 AM EST

Chronic Lymphocytic Leukemia

Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

Atlanta, GA

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
10
Friday
7:00 AM EST

Diffuse Large B-Cell Lymphoma

Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Atlanta, GA

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
10
Friday
7:00 AM EST

CAR-T Therapy

Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

Atlanta, GA

Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

December
10
Friday
7:00 AM EST

Acute Myeloid Leukemia

Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

Atlanta, GA

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:00 AM EST

Multiple Myeloma

A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

Atlanta, GA

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

December
10
Friday
7:00 AM EST

Sickle Cell Disease

The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Atlanta, GA

Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut

December
10
Friday
11:00 AM EST

Chronic Lymphocytic Leukemia

Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

Atlanta, GA

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

January
20
Thursday
6:00 PM PST

Hepatocellular Carcinoma

Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

San Francisco, CA

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
21
Friday
6:00 PM PST

Biliary Cancers

Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine

San Francisco, CA

Milind Javle, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
9
Wednesday
6:30 PM CST

Stroke

Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

New Orleans, LA

Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California

S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas

February
17
Thursday
6:45 PM PST

Renal Cell Carcinoma

Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies

San Francisco, CA

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

February
17
Thursday
6:45 PM PST

Bladder Cancer

Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

San Francisco, CA

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

February
18
Friday
6:15 PM PST

Prostate Cancer

Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

San Francisco, CA

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
25
Friday
6:30 PM EST

Multiple Sclerosis

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

West Palm Beach, FL

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland

*Participation in this CME event as an "outside activity"

February
28
Monday
6:30 AM MST

Severe Asthma

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Phoenix, AZ

Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California

March
10
Thursday
6:45 PM CST

Melanoma

Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Dallas, TX

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
11
Friday
4:45 PM CST

Breast Cancer

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

Dallas, TX

Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas

March
17
Thursday
5:00 PM CET

Alzheimer’s Disease

Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

Barcelona, Spain

Liana G. Apostolova, MS, MD, FAAN
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

March
22
Tuesday
6:00 AM PDT

Immuno-Oncology Biomarkers

Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Los Angeles, CA

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
23
Wednesday
6:00 AM PDT

HER2/HER3/TROP2 Testing/Treatment

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Los Angeles, CA

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
26
Saturday
6:30 PM EDT

Prurigo Nodularis

Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

Boston, MA

Sarina Elmariah, MD, PhD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Shawn Kwatra, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

March
27
Sunday
6:30 PM EDT

Chronic Spontaneous Urticaria

Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life

Boston, MA

Joseph Diaz, MD
Allergy, Asthma, & Immunology Associates of South Texas
San Antonio, Texas

Erika Gonzalez, MD
South Texas Allergy & Asthma Medical Professionals
University of Texas Health Science Center
San Antonio, Texas

April
9
Saturday
6:30 PM CDT

Cancer Immunotherapy

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

New Orleans

Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland

April
24
Sunday
12:00 PM MST

Graft-Versus-Host Disease

Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols

Salt Lake City, UT

Leslie Kean, MD, PhD
Harvard Medical School
Boston Children's Hospital
Dana-Farber Cancer Institute
Boston, Massachusetts

April
25
Monday
6:30 AM MDT

Acute Myeloid Leukemia

Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

Salt Lake City, UT

James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida

April
25
Monday
7:00 AM MDT

Leukemia

CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma

Salt Lake City, UT

Michael R. Bishop, MD
The David and Etta Jonas Center for Cellular Therapy
University of Chicago
Chicago, Illinois

April
26
Tuesday
6:30 AM MDT

Myelofibrosis

The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

Salt Lake City, UT

Jeanne M. Palmer, MD
Mayo Clinic
Phoenix, Arizona

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

April
26
Tuesday
6:30 AM MST

Chronic Lymphocytic Leukemia

Reaping the Rewards of Innovative Care in CLL: From Targeted Standards to Cellular Therapy

Salt Lake City, UT

John N. Allan, MD
Weill Cornell Medicine
New York, New York

Alexey V. Danilov, MD, PhD
Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California

April
26
Tuesday
11:30 AM MDT

Veno-Occlusive Disease

Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and Treatment

Salt Lake City, UT

Nelson Chao, MD, MBA
Duke Cancer Institute/Duke Global Health Institute
Durham, North Carolina

Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts

April
28
Thursday
11:45 AM PDT

Solid Tumors

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

Anaheim, CA

Linda Ahn, MSN, ANP-BC, AOCNP
Memorial Sloan Kettering Cancer Center
New York, New York

April
29
Friday
5:30 AM PDT

Chronic Lymphocytic Leukemia

Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

Anaheim, CA

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
30
Saturday
5:30 PM PDT

Renal Cell Carcinoma

Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based Therapies

Anaheim, CA

Nancy P. Moldawer, RN, MSN
Cedars-Sinai Medical Center
Los Angeles, California

May
5
Thursday
7:00 AM EDT

Neurofibromatosis

Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Pittsburgh, PA

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC

May
5
Thursday
12:15 PM EDT

Acute Lymphoblastic Leukemia

Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Pittsburgh, PA

Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota

Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia

May
14
Saturday
5:30 PM CDT
May
14
Saturday
12:00 PM EDT

NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Boston, MA

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

June
2
Thursday
6:30 AM EDT

Multiple Sclerosis

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

National Harbor, MD

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
3
Friday
6:30 PM CDT

Chronic Lymphocytic Leukemia

Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Chicago, Illinois

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
3
Friday
6:30 AM EDT

Multiple Sclerosis

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

National Harbor, MD

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

June
3
Friday
6:30 PM CDT

Melanoma

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Chicago, Illinois

Hussein A. Tawbi, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

June
3
Friday
6:30 PM CDT

AML

The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

Chicago, IL

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
3
Friday
6:30 PM CDT

Small Cell Lung Cancer

Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

Chicago, IL

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Friday
6:30 PM CDT

RCC

Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

Chicago, IL

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
5:30 AM CDT

DR/DME

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

New Orleans, Louisiana

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
12:30 PM EDT

COVID-19

Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

Boston, MA

Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

June
4
Saturday
6:30 PM CDT

CAR-T THERAPY

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice

Chicago, IL

Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
4
Saturday
6:30 PM CDT

HCC/LIVER CANCER

Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Chicago, IL

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

June
4
Saturday
6:30 PM CDT

NSCLC

Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Chicago, IL

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

June
4
Saturday
6:30 PM CDT

MULTIPLE MYELOMA

The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Chicago, IL

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
4
Saturday
6:30 PM CDT

HEAD AND NECK CANCER

The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

Chicago, IL

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
5
Sunday
6:30 PM CDT

NSCLC

Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

Chicago, IL

David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio

June
5
Sunday
6:30 PM CDT

MELANOMA

Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Chicago, IL

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia

June
5
Sunday
6:30 PM CDT

BASAL CELL CARCINOMA

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Chicago, IL

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
5
Sunday
6:30 PM CDT

BLADDER CANCER

Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum

Chicago, IL

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

June
5
Sunday
6:30 PM CDT

METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Chicago, IL

Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

June
9
Thursday
07:45 CEST

B-Cell Cancers

Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

Wien, Austria

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
9
Thursday
10:00 CEST

Chronic Lymphocytic Leukemia

New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management

Wien, Austria

Prof. Dr. med. Stephan Stilgenbauer
Comprehensive Cancer Center Ulm
Ulm University
Ulm, Germany

June
10
Friday
17:45 CEST

ACUTE LYMPHOBLASTIC LEUKEMIA

The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients

Wien, Austria

Prof. Carmelo Rizzari
President of the European Society of Pediatric Oncology (SIOPE)
Professor of Pediatrics
University of Milano-Bicocca
Head, Pediatric Hematology Oncology Unit
MBBM Foundation, ASST Monza
Monza, Italy

June
15
Wednesday
11:45 AM EDT
July
1
Friday
13:25 CEST

Gastric Cancer

Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Barcelona, Spain

Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York

July
23
Saturday
7:00 AM PDT

Prurigo Nodularis

Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

Vancouver, BC

Sarah S. Chisolm, MD
Emory University
VISN 7, VA
Atlanta, Georgia

Brian S. Kim, MD, MTR
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
New York, New York

September
9
Friday
10:00 CEST

Breast Cancer

Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

Paris, France

Professor Aleix Prat, MD, PhD
Hospital Clínic Barcelona
University of Barcelona
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Barcelona, Spain

September
9
Friday
18:00 CEST
September
24
Saturday
7:00 PM CDT
September
25
Sunday
6:30 AM CDT

NSCLC

Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations

Chicago, IL

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada

September
28
Wednesday
12:41 PM CDT

ACUTE MYELOID LEUKEMIA

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Houston, TX

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

September
28
Wednesday
12:41 PM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Houston, TX

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Deborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

September
29
Thursday
11:50 AM CDT

MULTIPLE MYELOMA

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Houston, TX

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
30
Friday
12:15 PM EDT

NSCLC

Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings

New York, NY

Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

September
30
Friday
6:30 PM EDT

NSCLC

Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right

New York, NY

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

September
30
Friday
6:30 PM CDT

MULTIPLE MYELOMA

The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity

Chicago, IL

Praneetha Thulasi, MD
Emory Eye Center
Emory University School of Medicine
Atlanta, Georgia

Jonathan L. Kaufman, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

October
1
Saturday
5:30 PM EDT

GENERALIZED MYASTHENIA GRAVIS

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

National Harbor, MD

James F. Howard Jr., MD
The University of North Carolina
Chapel Hill, North Carolina

October
2
Sunday
6:30 AM EDT

Hypertrophic Cardiomyopathy

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

National Harbor, MD

Milind Desai, MD, MBA
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland, Ohio

October
14
Friday
6:00 PM EDT

EOSINOPHILIC ESOPHAGITIS

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Orlando, FL

Sandeep K. Gupta, MD
Community Health Network
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana

October
17
Monday
6:15 AM CDT

ASTHMA

Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma

Nashville, TN

Leonard B. Bacharier, MD
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, Tennessee

Monica Kraft, MD
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York

October
23
Sunday
6:00 PM CDT

SOLID TUMORS

Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors

San Antonio, TX

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

November
3
Thursday
6:30 PM CDT

RENAL CELL CARCINOMA

RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World

Austin, Texas

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
5
Saturday
6:00 AM CDT
November
5
Saturday
1:00 PM EDT

HCC/LIVER CANCER

It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics

Washington, DC

Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas

November
5
Saturday
5:30 PM CDT

HEART FAILURE

How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

Chicago, IL

Javed Butler, MD, MPH, MBA
Baylor Scott and White Research Institute
Dallas, Texas
University of Mississippi
Jackson, Mississippi

November
7
Monday
6:00 AM CST

HYPERLIPIDEMIA

Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies

Chicago, IL

Peter H. Jones, MD, MNLA
Center for Cardiometabolic Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, Texas

R. Scott Wright, MD
Mayo Clinic
Rochester, Minnesota

November
12
Saturday
8:00 PM EST

SEVERE ASTHMA

Leveling the Playing Field for All Patients With Severe Asthma: Directing New Treatment Approaches at the Airway Epithelium

Louisville, KY

Juan Carlos Cardet, MD
University of South Florida
Tampa, Florida

Geoffrey L. Chupp, MD
Yale School of Medicine
Yale Center for Asthma and Airway Disease
Yale New Haven Hospital
New Haven, Connecticut

November
15
Tuesday
7:30 AM EST

LUPUS

How I Think, How I Treat—Assessing, Managing, and Engaging Patients to Optimize Care in SLE and LN: Comparing Approaches With the Experts

Philadelphia, PA

Maureen A. McMahon, MD
UCLA David Geffen School of Medicine
Los Angeles, California

November
16
Wednesday
12:15 CET

BREAST CANCER

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

Barcelona, Spain

Professor Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
Bart's Cancer Institute, Queen Mary University of London
London, England, United Kingdom

November
17
Thursday
5:15 PM EST

GLIOBLASTOMA

Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches

Tampa, FL

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

November
17
Thursday
7:00 PM PST

DESMOID TUMORS

On the Cusp of Change: Modernizing the Treatment of Desmoid Tumors With Novel Gamma Secretase Inhibitors

Vancouver, BC

Bernd Kasper, MD, PhD
University of Heidelberg
Mannheim Cancer Center (MCC)
Mannheim, Germany

November
28
Monday
1:30 PM CST

ALZHEIMER'S DISEASE

Revealing the Neuropathology of Alzheimer’s Disease Through Novel Fluid and Imaging Biomarkers: Ushering in a Precision Era of Diagnosis and Treatment

Chicago, Illinois

Val J. Lowe, MD
Mayo Clinic
Rochester, Minnesota

Jonathan E. McConathy, MD, PhD
University of Alabama at Birmingham
Heersink School of Medicine
Birmingham, Alabama

November
30
Wednesday
6:30 AM PST

BLADDER CANCER

Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All

San Diego, CA

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Center
Seattle, Washington

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina

November
30
Wednesday
11:30 AM PST

PROSTATE CANCER

Case by Case: Maximizing Personalized Approaches to Prostate Cancer

San Diego, CA

Rana R. McKay, MD
UC San Diego Moores Cancer Center
University of California San Diego
La Jolla, California

Alicia K. Morgans, MD, MPH
Dana-Farber Cancer Center
Boston, Massachusetts

December
6
Tuesday
7:00 PM CST

BREAST CANCER

Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer

San Antonio, TX

Erika Hamilton, MD
Sarah Cannon Research
Institute/Tennessee Oncology
Nashville, Tennessee

December
7
Wednesday
10:45 AM PST

CHRONIC KIDNEY DISEASE

Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

Las Vegas, NV

Jay B. Wish, MD
Indiana University Health
Indianapolis, Indiana

December
9
Friday
7:00 AM CST

LYMPHOMA

The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care

New Orleans, LA

Jason Westin, MD, MS, FACP
The University of Texas
MD Anderson Cancer Center
Houston, Texas

December
9
Friday
7:00 AM CST

COLD AGGLUTININ DISEASE (CAD)

Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs

New Orleans, LA

Sigbjørn Berentsen, MD, PhD
Haugesund Hospital
Haugesund, Norway

Ilene C. Weitz, MD
Keck-USC School of Medicine
Los Angeles, California

December
9
Friday
7:00 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

New Orleans, LA

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
9
Friday
7:00 AM CST

DIFFUSE LARGE B-CELL LYMPHOMA

Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care

New Orleans, LA

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
9
Friday
7:00 AM CST

MULTIPLE MYELOMA

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

New Orleans, LA

Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts

December
9
Friday
7:00 AM CST

LEUKEMIA

The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care

New Orleans, LA

Vivian G. Oehler, MD
Fred Hutchinson Cancer Center
University of Washington
Seattle, Washington

December
9
Friday
7:00 AM CST

LYMPHOMA

Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management

New Orleans, LA

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

December
9
Friday
7:00 AM CST

ACUTE MYELOID LEUKEMIA

Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations

New Orleans, LA

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

December
9
Friday
11:00 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

New Orleans, LA

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
9
Friday
3:00 PM CST

MYELODYSPLASTIC SYNDROMES

The Future Is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management

New Orleans, LA

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

January
19
Thursday
5:45 PM PST

GI MALIGNANCIES

Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations

San Francisco, CA

Vivek Subbiah, MD
The University of Texas MD Anderson Cancer Center
MD Anderson Cancer Center Network
Houston, Texas

January
19
Thursday
5:45 PM PST

HCC

The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York

January
20
Friday
6:00 PM EST

CHRONIC LYMPHOCYTIC LEUKEMIA

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

New York, NY

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

January
20
Friday
5:30 PM PST

BILIARY CANCER

Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents

San Francisco, CA

Rachna T. Shroff, MD, MS
University of Arizona Cancer Center (UACC)
UA College of Medicine – Tucson (UA COM-T)
Tucson, Arizona

January
21
Saturday
12:10 PM PST

NSCLC

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances

San Diego, CA

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

January
22
Sunday
12:40 PM PST

NSCLC

EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know

San Diego, CA

Catherine Shu, MD
Columbia University Medical Center
New York, New York

February
15
Wednesday
1:00 PM EST

VENO-OCCLUSIVE DISEASE

New Rules for VOD/SOS: Modern Risk Assessment, Diagnostic Principles, and Innovative Treatment

Orlando, FL

Prof. Mohamad Mohty
Saint-Antoine Hospital
Sorbonne University
Paris, France

Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts

February
15
Wednesday
1:00 PM EST

MULTIPLE MYELOMA

Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody Options

Orlando, FL

Thomas G. Martin, III, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
16
Thursday
7:30 AM EST

GRAFT-VERSUS-HOST DISEASE

Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease

Orlando, FL

Stephanie Lee, MD, MPH
Fred Hutch Cancer Center
University of Washington
Seattle, Washington

February
16
Thursday
12:45 PM EST

ACUTE MYELOID LEUKEMIA

The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

Orlando, FL

James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida

Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

February
16
Thursday
6:45 PM PST

RCC

Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic Strategies

San Francisco, CA

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

February
16
Thursday
6:45 PM PST

BLADDER CANCER

Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

San Francisco, CA

Matthew I. Milowsky, MD, FASCO
University of North Carolina at Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

February
17
Friday
7:30 AM EST

CELLULAR THERAPY

The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence

Orlando, FL

Olalekan Oluwole, MBBS, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

February
17
Friday
6:15 PM PST

PROSTATE CANCER

Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care

San Francisco, CA

Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

February
18
Saturday
7:30 AM EST

CLL

Finding Treatment Synergy in CLL: Expert Consults on Advances With Targeted and Cellular Therapy

Orlando, FL

Mazyar Shadman, MD, MPH
Fred Hutchinson Cancer Center and University of Washington
Seattle, Washington

Peter A. Riedell, MD
The David and Etta Jonas Center for Cellular Therapy
University of Chicago
Chicago, Illinois

February
22
Wednesday
3:15 PM PST

SCLC

Facilitating Progress in the Treatment of SCLC: How to Optimize the Use of Current Systemic Options and Accelerate the Clinical Transition of Investigational Approaches

Santa Monica, CA

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

February
23
Thursday
6:00 PM PST

NSCLC

Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum

Santa Monica, CA

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada

February
24
Friday
7:30 AM PST

MULTIPLE SCLEROSIS

BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?

San Diego, CA

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Jiwon Oh, MD, PhD, FRCPC
St. Michael’s Hospital
University of Toronto
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

February
24
Friday
6:15 PM PST

NSCLC

Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC

Santa Monica, CA

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

February
25
Saturday
12:45 PM EST

BREAST CANCER

A Practical Case-Based Approach to Navigating the Complexities of Advanced- and Early-Stage HR+/HER2- Breast Cancer

Atlanta, GA

Erica L. Mayer, MD, MPH
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

March
5
Sunday
6:15 AM CST

HYPERTROPHIC CARDIOMYOPATHY (HCM)

Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment

New Orleans, LA

Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

March
13
Monday
6:00 AM CDT

BREAST CANCER

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment

New Orleans, LA

Stuart J. Schnitt, MD
Dana-Farber/Brigham and Women’s Cancer Center
Harvard Medical School
Boston, Massachusetts

Paolo Tarantino, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

March
13
Monday
6:30 AM CDT

MYELODYSPLASTIC SYNDROMES

Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment

New Orleans, LA

Rami Komrokji, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Cecilia CS Yeung, MD
Fred Hutch Cancer Center
University of Washington
Fred Hutch Clinical Testing Laboratories
Seattle, Washington

March
14
Tuesday
6:00 AM CDT

AML

The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings

New Orleans, LA

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Joseph D. Khoury, MD, FCAP
University of Nebraska Medical Center
Omaha, Nebraska

March
14
Tuesday
6:30 AM CDT

IMMUNO-ONCOLOGY BIOMARKERS

Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment

New Orleans, LA

Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

March
16
Thursday
7:00 PM CDT

PRURIGO NODULARIS

Moving Beyond Off-Label Management in Prurigo Nodularis: Exploring New Treatment Options

New Orleans, LA

Sarina B. Elmariah, MD, PhD, MPH
University of California
San Francisco, California

Shawn Kwatra, MD
Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

March
23
Thursday
7:00 PM EDT

MELANOMA

Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies

Boston, MA

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
23
Thursday
7:00 PM EDT

BREAST CANCER

Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer

Boston, MA

Laura S. Dominici, MD, FACS
Harvard Medical School
Brigham and Women's Faulkner Hospital
Dana-Farber Brigham Cancer Center
Brigham and Women's Hospital
Boston, Massachusetts

March
25
Saturday
11:15 AM EDT

ENDOMETRIAL CANCER

Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care

Tampa, FL

David M. O'Malley, MD
The James Cancer Hospital and Solove Research Institute
The Ohio State University College of Medicine
Columbus, Ohio

March
31
Friday
6:30 AM MST

CHRONIC LYMPHOCYTIC LEUKEMIA

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Phoenix, AZ

Emily K. Dotson, PharmD, BCOP
The James Cancer Hospital
Columbus, Ohio

April
16
Sunday
12:00 PM HAST

NON-CYSTIC FIBROSIS BRONCHIECTASIS

Improving Time to Diagnosis of Non–Cystic Fibrosis Bronchiectasis: The Importance of the Radiologist in Fulfilling Unmet Needs of Patients

Honolulu, HI

Charles L. Daley, MD
National Jewish Health
Denver, Colorado

Mary M. Salvatore, MD
Columbia University Irving Medical Center
New York, New York

April
20
Thursday
1:00 PM EDT

OBESITY

Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of Obesity as a Chronic Disease

New York, NY

Jaime Almandoz, MD, MBA, FTOS
University of Texas Southwestern Medical Center
Dallas, Texas

Angela Fitch, MD, FACP, FOMA
knownwell, inc.
Obesity Medicine Association
Boston, Massachusetts

April
26
Wednesday
5:30 PM CDT

GYNECOLOGIC CANCERS

Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

San Antonio, TX

Kimberly Halla, MSN, FNP-C
CaroMont Regional Medical Center
Gastonia, North Carolina

April
26
Wednesday
6:00 PM PDT

ALZHEIMER'S DISEASE

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

San Diego, CA

Anna Chodos, MD, MPH
Zuckerberg San Francisco General Hospital
University of California
San Francisco, California

Ian Neel, MD
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California

April
27
Thursday
5:30 AM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Leading Change, Leading Advances in CLL Care: Guidance on Delivering Modern Targeted and Cellular Therapeutics

San Antonio, TX

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
University of California San Francisco
San Francisco, California

April
27
Thursday
7:30 PM CDT

MULTIPLE MYELOMA

Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy

San Antonio, TX

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Case Comprehensive Cancer Center
Cleveland Ohio

April
28
Friday
5:30 PM CDT

NSCLC

Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

San Antonio, TX

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Yale School of Nursing
Yale Comprehensive Cancer Center & Smilow Cancer Center
New Haven, Connecticut

April
29
Saturday
6:00 AM CDT

BLADDER CANCER

Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care

San Antonio, TX

Brenda Martone, MSN, ANP-BC, AOCNP
Northwestern Medicine
Chicago, Illinois

May
6
Saturday
12:00 PM PDT

NSCLC

Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC

Los Angeles, CA

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
8
Monday
12:15 PM PDT

NSCLC

Bringing Precision Lung Cancer Care to the Perioperative Space: How to Maximize the Impact of EGFR-Targeted Therapy in Resectable NSCLC

Los Angeles, CA

Catherine Shu, MD
Columbia University Medical Center
New York, New York

Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

May
8
Monday
6:00 PM CDT

IBD

Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis

Chicago, IL

Miguel Regueiro, MD
Digestive Disease and Surgery Institute
Cleveland Clinic
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio

May
10
Wednesday
11:00 AM CDT

NEUROFIBROMATOSIS TYPE 1

The Bedrock of Personalized NF1 Care: Fundamentals of Managing NF1-Associated PNs and Other Tumors With Innovative Targeted Therapy

Fort Worth, TX

Laura Klesse, MD, PhD
UT Southwestern Medical Center
Dallas, Texas

Carlos G. Romo, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

May
11
Thursday
12:15 PM CDT

ACUTE LYMPHOBLASTIC LEUKEMIA

Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy

Fort Worth, TX

Luke Maese, DO
University of Utah - Huntsman Cancer Institute
Primary Children's Hospital
Salt Lake City, Utah

Rachel Rau, MD
Texas Children's Cancer and Hematology Center
Baylor College of Medicine
Houston, Texas

June
1
Thursday
6:30 AM MDT

MULTIPLE SCLEROSIS

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Aurora, CO

Amit Bar-Or, MD, FRCPC
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
2
Friday
7:00 AM EDT

HYPERLIPIDEMIA

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents

Atlanta, GA

P. Barton Duell, MD
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

June
2
Friday
6:30 PM CDT

IMMUNE THROMBOCYTOPENIA

New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes

Chicago, IL

David J. Kuter, MD, DPhil
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Cindy Neunert, MD, MSCS
Columbia University Irving Medical Center
New York, New York

June
2
Friday
6:30 PM CDT

HEAD AND NECK CANCER

Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care

Chicago, IL

Barbara Burtness, MD
Yale Cancer Center
New Haven, Connecticut

June
2
Friday
6:30 PM CDT

HCC/LIVER CANCER

Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms

Chicago, IL

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York

June
2
Friday
6:30 PM CDT

RENAL CELL CARCINOMA

Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum

Chicago, IL

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

June
2
Friday
6:30 PM CDT

CLL

Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies

Chicago, IL

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Saturday
6:30 AM MDT

MULTIPLE SCLEROSIS

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Aurora, CO

Jiwon Oh, MD, PhD, FRCPC
St. Michael’s Hospital
University of Toronto
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

June
3
Saturday
6:30 PM CDT

NSCLC

Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care

Chicago, IL

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

June
3
Saturday
6:30 PM CDT

ENDOMETRIAL CANCER

Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

Chicago, IL

David M. O'Malley, MD
The James Cancer Hospital and Solove Research Institute
The Ohio State University College of Medicine
Columbus, Ohio

June
3
Saturday
6:30 PM CDT

MULTIPLE MYELOMA

The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms

Chicago, IL

Robert Z. Orlowski, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
3
Saturday
6:30 PM CDT

ACUTE MYELOID LEUKEMIA

Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management

Chicago, IL

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
3
Saturday
6:30 PM CDT

MELANOMA

Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options

Chicago, IL

Jason J. Luke, MD, FACP
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, Pennsylvania

June
4
Sunday
6:30 PM CDT

SCLC

Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research

Chicago, IL

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

June
6
Tuesday
12:45 PM PDT

COVID-19

What’s New, and What’s Next? Customizing COVID-19 Prevention Approaches in Transplant Patients to Increase Uptake, Access, and Efficacy

San Diego, CA

Shmuel Shoham, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

Ghady Haidar, MD
University of Pittsburgh and UPMC
Pittsburgh, Pennsylvania

June
13
Tuesday
16:15 CEST

MANTLE CELL LYMPHOMA

Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

Lugano, Switzerland

Prof. Dr. Martin Dreyling
LMU University Hospital
Munich, Germany

June
24
Saturday
11:30 AM EDT

HEMOPHILIA

Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products

Montréal, Québec, Canada

Steven W. Pipe, MD
University of Michigan
Ann Arbor, Michigan

Maria Elisa Mancuso, MD, PhD
Center for Thrombosis and Hemorrhagic Diseases
IRCCS Humanitas Research Hospital, Rozzano
Humanitas University, Pieve Emanuele
Milan, Italy

June
25
Sunday
6:30 AM CDT

ALZHEIMER’S DISEASE

Navigating the New Era of Molecularly-Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

Chicago, IL

Gil Rabinovici, MD
UCSF Alzheimer’s Disease Research Center
University of California, San Francisco
San Francisco, California

Ilya M. Nasrallah, MD, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

July
17
Monday
12:45 CEST

ALZHEIMER’S DISEASE

Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA)

Amsterdam, Netherlands

Stephen P. Salloway, MD, MS
Alpert Medical School of Brown University
Brown Center for Alzheimer’s Disease Research
Providence, Rhode Island

August
18
Friday
7:15 AM EDT

HEMOPHILIA

Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A

Fort Washington, MD

Stacy E. Croteau, MD, MMS
Boston Children’s Hospital
Boston Hemophilia Center
Harvard Medical School
Boston, Massachusetts

Steven W. Pipe, MD
University of Michigan
Ann Arbor, Michigan

September
6
Wednesday
11:51 AM CDT

MYELODYSPLASTIC SYNDROME

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy

Houston, TX

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amy E. DeZern, MD, MHS
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

September
6
Wednesday
11:51 AM CDT

MULTIPLE MYELOMA

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care

Houston, TX

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

September
6
Wednesday
7:35 PM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations

Houston, TX

William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Nicole Lamanna, MD
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

September
7
Thursday
6:45 AM CDT

ACUTE MYELOID LEUKEMIA

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms

Houston, TX

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Gail J. Roboz, MD
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

September
9
Saturday
11:45 SGT

NSCLC

A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations

Singapore

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

September
10
Sunday
5:45 AM EDT

RETT SYNDROME

The Changing Future for Patients With Rett Syndrome and Their Families: Early Diagnosis and Emerging Therapies to Reduce the Burdens of Disease

Philadelphia, PA

Jeffrey L. Neul, MD, PhD
Vanderbilt Kennedy Center
Vanderbilt University Medical Center
Nashville, Tennessee

Alan K. Percy, MD
University of Alabama
Birmingham, Alabama

September
12
Tuesday
13:00 SGT
September
29
Friday
6:15 AM CDT

MYELODYSPLASTIC SYNDROMES

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care

Chicago, Illinois

Michael R. Savona, MD
Vanderbilt University School of Medicine
Nashville, Tennessee

Andrew M. Brunner, MD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

October
1
Sunday
6:00 PM PDT

SOLID TUMORS

Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond

San Diego, CA

Erik P. Sulman, MD, PhD
Laura and Isaac Perlmutter Cancer Center
Vilcek Institute of Graduate Biomedical Sciences/NYU Grossman School of Medicine
NYU Langone Health
New York, New York

October
2
Monday
11:00 CEST

DIABETES

Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care

Hamburg, Germany

Hiddo J.L. Heerspink, PhD, PharmD
University Medical Center Groningen
Groningen, Netherlands

Prof. Dr. med Christoph Wanner
University Hospital of Würzburg
Würzburg, Germany

October
5
Thursday
7:15 PM PDT

EOSINOPHILIC ESOPHAGITIS

Living With Eosinophilic Esophagitis: Recognizing the Burden on Patients and Integrating Targeted Therapy to Improve Outcomes

San Diego, CA

Seema S. Aceves, MD, PhD
University of California
Eosinophilic Gastrointestinal Disorders Clinic
Rady Children’s Hospital
San Diego, California

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

October
6
Friday
6:30 PM MDT

MYASTHENIA GRAVIS

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

Denver, CO

James F. Howard Jr., MD
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

October
7
Saturday
7:00 AM EDT

DEPRESSION

Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Lake Buena Vista, FL

Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
The Hamilton Group Behavioral Health LLC
Las Vegas, Nevada

Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Rasmussen University
Bloomington, Minnesota

October
7
Saturday
12:40 PM EDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy

Boston, MA

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

October
8
Sunday
6:45 AM EDT

HYPERTROPHIC CARDIOMYOPATHY

Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond

Cleveland, Ohio

Milind Desai, MD, MBA
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland, Ohio

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

October
9
Monday
6:00 AM EDT

ANTICOAGULATION REVERSAL

Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding

Philadelphia, PA

Truman J. Milling Jr., MD, FACEP
Seton Dell Medical School Stroke Institute
Austin, Texas

October
12
Thursday
4:30 PM EDT

OBESITY

Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

Gainesville, FL

W. Troy Donahoo, MD, FTOS
University of Florida College of Medicine
Gainesville, Florida

Amy J. Sheer, MD, MPH
University of Florida College of Medicine
Gainesville, Florida

October
15
Sunday
6:30 PM CDT

OBESITY

Leading the Charge to Change the Obesity Narrative: Supporting Primary Care to Improve Weight Management Discussions, Diagnosis, and Decisions

Dallas, TX

Jaime Almandoz, MD, MBA, FTOS
University of Texas Southwestern Medical Center
Dallas, Texas

Angela Fitch, MD, FACP, FOMA
knownwell, inc.
Obesity Medicine Association
Boston, Massachusetts

October
21
Saturday
6:30 PM EDT

Rett Syndrome

Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management

Washington, DC

Eric Marsh, MD, PhD
Intellectual and Developmental Disabilities Research Center
Children’s Hospital of Philadelphia
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

November
9
Thursday
2:00 PM EST

SOLID TUMORS

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

Orlando, FL

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Yale Comprehensive Cancer Center & Smilow Cancer Center
Yale School of Nursing
New Haven, Connecticut

November
9
Thursday
7:00 PM PST

PSORIASIS

Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

Indian Wells, California

April W. Armstrong, MD, MPH
University of California, Los Angeles (UCLA)
Los Angeles, California

Tina Bhutani, MD, MAS
Psoriasis and Skin Treatment Center
University of California
San Francisco, California

November
10
Friday
6:45 PM CST

RENAL CELL CARCINOMA

Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings

Nashville, TN

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
11
Saturday
8:00 PM PST

SEVERE ASTHMA

Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

Anaheim, CA

Jonathan Corren, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

Mario Castro, MD
Frontiers Clinical and Translational Science Institute at the University of Kansas
University of Kansas School of Medicine
Kansas City, Kansas

November
12
Sunday
6:00 PM EST

THROMBOSIS

Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

Philadelphia, PA

Roxana Mehran, MD
The Center for Interventional Cardiovascular Research and Clinical Trials
Center for Women’s Heart Health at Mount Sinai
New York, New York

Jeffrey Weitz, MD, FRCPC, FRSC, FACP
McMaster University
Thrombosis & Atherosclerosis Research Institute
Hamilton, Ontario, Canada

November
16
Thursday
5:15 PM PST

GLIOBLASTOMA

Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches

Vancouver, BC, Canada

Steven Brem, MD
Hospital of the University of Pennsylvania
Penn Brain Tumor Center
Abramson Cancer Center
Philadelphia, Pennsylvania

November
29
Wednesday
6:45 AM EST

BLADDER CANCER

Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

Washington, DC

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina

November
30
Thursday
6:00 AM CST

NSCLC

Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care

New Orleans, LA

Matthew A. Gubens, MD, MS, FASCO
University of California San Francisco
San Francisco, California

December
1
Friday
11:30 AM EST

PROSTATE CANCER

Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

Washington, DC

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina

December
3
Sunday
6:30 AM CST

NSCLC

Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer

Chicago, IL

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

December
3
Sunday
6:30 AM CST

SCLC

Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

Chicago, IL

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

December
5
Tuesday
7:00 PM CST

Metastatic HER2-Positive Breast Cancer

Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer

San Antonio, TX

Sara A Hurvitz, MD, FACP
University of Washington Medicine
Fred Hutchinson Cancer Center
Seattle, Washington

December
6
Wednesday
7:00 PM CST
December
8
Friday
7:00 AM PST

MULTIPLE MYELOMA

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

San Diego, CA

Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts

December
8
Friday
7:00 AM PST

MYELODYSPLASTIC SYNDROMES

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and Treatment

San Diego, CA

María Díez Campelo, MD, PhD
University Hospital of Salamanca, IBSAL
Salamanca, Spain

December
8
Friday
11:00 AM PST

CHRONIC LYMPHOCYTIC LEUKEMIA

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

San Diego, CA

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
8
Friday
3:00 PM PST
December
8
Friday
3:00 PM PST

ACUTE MYELOID LEUKEMIA

Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

San Diego, CA

Sergio A. Giralt, MD, FACP
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York

Selina Luger, MD, FRCPC
Perelman School of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

January
18
Thursday
5:15 PM PST

HCC

Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

San Francisco, CA

Ghassan Abou-Alfa, MD, MBA
New York, New York
Memorial Sloan Kettering Cancer Center
Weill Cornell College at Cornell University
Trinity College Dublin

January
18
Thursday
5:15 PM PST
January
19
Friday
5:45 PM CST

MANTLE CELL LYMPHOMA

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

Chicago, IL

Nirav Shah, MD, MS
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Krish Patel, MD
Center for Blood Disorders and Cellular Therapy
Swedish Cancer Institute
Seattle, Washington

January
25
Thursday
6:00 PM PST

RCC

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

San Francisco, CA

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

January
25
Thursday
6:00 PM PST

PROSTATE CANCER

Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

San Francisco, CA

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

January
26
Friday
6:45 PM PST

BLADDER CANCER

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

San Francisco, CA

Matthew D. Galsky, MD
Icahn School of Medicine at Mount Sinai
Tisch Cancer Institute
New York, New York

January
27
Saturday
7:30 AM PST

HCC

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist—Oncologist Collaboration Across the Disease Continuum

Long Beach, CA

Lipika Goyal, MD, MPhil
Stanford School of Medicine
Palo Alto, California

Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois

January
28
Sunday
5:55 AM CST

NSCLC

A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

San Antonio, TX

Jessica Donington, MD
The University of Chicago Medicine
Chicago, Illinois

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

January
28
Sunday
11:40 AM CST

NSCLC

Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC

San Antonio, TX

Brendon M. Stiles, MD
Montefiore Einstein Comprehensive Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York

February
21
Wednesday
12:00 PM CST

VOD

Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

San Antonio, TX

Prof. Mohamad Mohty
Saint-Antoine Hospital
Sorbonne University
Paris, France

Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts

February
21
Wednesday
3:30 PM PST
February
22
Thursday
12:00 PM CST

CMV

Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents 

San Antonio, TX

Roy F. Chemaly, MD, MPH, FIDSA, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

Genovefa Papanicolaou, MD, FIDSA
Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine
New York, New York

February
23
Friday
6:45 AM PST

NSCLC

The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

Santa Monica, CA

Sandip Patel, MD
University of California San Diego
Sanford Stem Cell Clinical Center
La Jolla, California

February
23
Friday
12:00 PM CST

MULTIPLE MYELOMA

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

San Antonio, TX

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
23
Friday
5:25 PM PST

NSCLC

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Santa Monica, CA

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

February
24
Saturday
6:30 AM CST

ACUTE MYELOID LEUKEMIA

Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

San Antonio, TX

Sergio A. Giralt, MD, FACP
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York

Brittany Knick Ragon, MD
Levine Cancer Institute, Atrium Health
Wake Forest University School of Medicine
Charlotte, North Carolina

February
24
Saturday
6:45 AM PST

SCLC

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Santa Monica, CA

Taofeek K. Owonikoko, MD, PhD
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland School of Medicine
University of Maryland, Baltimore
University of Maryland Medical Center
Baltimore, Maryland

February
24
Saturday
12:00 PM CST

CAR-T THERAPY

Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy

San Antonio, TX

Olalekan Oluwole, MBBS, MPH
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

March
8
Friday
13:30 CET

CHRONIC LYMPHOCYTIC LEUKEMIA

Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations

Vienna, Austria

Prof. Dr. med. Stephan Stilgenbauer
Comprehensive Cancer Center Ulm
Ulm University
Ulm, Germany

March
8
Friday
6:30 PM PST

CHRONIC SPONTANEOUS URTICARIA

Advancing Patient Care in Chronic Spontaneous Urticaria: Reshaping the Future With Targeted Biologic Therapies

San Diego, CA

April W. Armstrong, MD, MPH
University of California, Los Angeles (UCLA)
Los Angeles, California

Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI
Specialist, Clinical Immunology and Allergy and Internal Medicine
Toronto, Ontario, Canada

March
17
Sunday
7:00 AM PDT

GYNECOLOGIC CANCERS

Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care

San Diego, CA

Bradley J. Monk, MD, FACS, FACOG
Florida Cancer Specialists and Research Institute
West Palm Beach, Florida

March
18
Monday
12:00 PM PDT

ENDOMETRIAL/OVARIAN CANCER

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

San Diego, CA

Kathleen N. Moore, MD, MS
Stephenson Cancer Center at the University of Oklahoma HSC
Oklahoma City, Oklahoma

March
21
Thursday
7:00 PM EDT

MELANOMA

New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy

Atlanta, GA

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
21
Thursday
7:00 PM EDT

BREAST CANCER

Unraveling the Complex Choices in Early Breast Cancer: A Roadmap to Informed Multidisciplinary Decisions About Assessment and Treatment

Atlanta, GA

Laura S. Dominici, MD, FACS
Harvard Medical School
Brigham and Women's Faulkner Hospital
Dana-Farber Brigham Cancer Center
Brigham and Women's Hospital
Boston, Massachusetts

March
27
Wednesday
11:55 AM MDT

HCC

The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Continuum

Salt Lake City, UT

Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Lipika Goyal, MD, MPhil
Stanford School of Medicine
Palo Alto, California

April
3
Wednesday
6:30 AM EDT

MULTIPLE MYELOMA

Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms

Tampa, FL

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Emory University School of Medicine
Winship Cancer Institute of Emory University
Atlanta, Georgia

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
The University of Kansas Cancer Center
Kansas City, Kansas

April
3
Wednesday
11:15 AM PDT

NEUROFIBROMATOSIS TYPE 1

Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 PNs and Other Tumors

Seattle, WA

Carlos G. Romo, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

Aimee Sato, MD
Seattle Children’s
UW Medicine
Seattle, Washington

April
6
Saturday
6:00 PM EDT

CRSwNP

Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

Covington, KY

Joseph K. Han, MD
Eastern Virginia Medical School
Norfolk, Virginia

Seth J. Isaacs, MD
TriHealth
Good Samaritan Hospital
Cincinnati, Ohio

April
17
Wednesday
11:30 AM CDT

HCM

Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy

New Orleans, LA

Milind Desai, MD, MBA, FACC, FAHA, FESC
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland Clinic
Cleveland, Ohio

Andrew Willeford, PharmD, PhD, BCCP
UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
La Jolla, California

April
17
Wednesday
6:00 PM EDT

TYPE 2 DIABETES

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

Boston, MA

John E. Anderson, MD
The Frist Clinic
Nashville, Tennessee

Javier Morales, MD, FACP, FACE
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Advanced Internal Medicine Group, PC
East Hills, New York

April
20
Saturday
8:30 AM EDT

OBESITY

Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

Gainesville, FL

Amy J. Sheer, MD, MPH
University of Florida College of Medicine
Gainesville, Florida

April
25
Thursday
5:30 AM EDT

NSCLC

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care

Washington, DC

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Yale Comprehensive Cancer Center & Smilow Cancer Center
Yale School of Nursing
New Haven, Connecticut

Beth Sandy, MSN, CRNP, FAPO
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

April
26
Friday
5:30 AM EDT

MULTIPLE MYELOMA

Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations

Washington, DC

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Case Comprehensive Cancer Center
Cleveland, Ohio

April
27
Saturday
12:00 PM EDT

NSCLC

Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches

Toronto, Ontario, Canada

Jessica Donington, MD
The University of Chicago Medicine
Chicago, Illinois

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
3
Friday
8:00 AM CDT

BLADDER CANCER

Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum

San Antonio, TX

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
Myrtle Beach, South Carolina

May
16
Thursday
12:15 CEST

BREAST CANCER

Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

Berlin, Germany

Professor Stephen Johnston, MA, PhD
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
Chelsea, London, United Kingdom

May
19
Sunday
6:00 PM EDT

METABOLIC DYSFUNCTION–ASSOCIATED STEATOHEPATITIS

Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

Washington, DC

Rohit Loomba, MD, MHSc
MASLD Research Center
University of California at San Diego
La Jolla, California

May
19
Sunday
6:30 p.m. PT

NCFBE

Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options

San Diego, CA

Doreen J. Addrizzo-Harris, MD
NYU School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
Newport Beach, California

May
21
Tuesday
7:30 AM PDT

ALZHEIMER'S DISEASE

Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment

Las Vegas, NV

Val J. Lowe, MD
Mayo Clinic
Rochester, Minnesota

Cyrus A. Raji, MD, PhD
Washington University
St. Louis, Missouri

May
31
Friday
6:30 AM CDT

MULTIPLE SCLEROSIS

Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS

Nashville, TN

Amit Bar-Or, MD, FRCPC
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Jiwon Oh, MD, PhD, FRCPC
St. Michael’s Hospital
University of Toronto
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

May
31
Friday
6:30 PM CDT

HER2+ GI MALIGNANCIES

Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

Chicago, IL

Yelena Y. Janjigian*, MD
Memorial Sloan Kettering Cancer Center
New York, New York

* This activity was developed with Yelena Y. Janjigian, MD, and is not affiliated in any capacity with Memorial Sloan Kettering Cancer Center.

May
31
Friday
6:30 PM CDT

BREAST CANCER

Advancing Novel Therapies for HER2-Positive, HER2-Low, and HR-Positive Breast Cancer: Solutions for Selecting and Sequencing Therapeutic Approaches

Chicago, IL

Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
New York, New York

June
1
Saturday
6:30 PM CDT

ADCs IN BLADDER CANCER

Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care

Chicago, IL

Petros Grivas, MD, PhD
University of Washington School of Medicine
Fred Hutchinson Cancer Center
Seattle, Washington

June
1
Saturday
6:30 PM CDT

PROSTATE CANCER

Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

Chicago, IL

Karim Fizazi, MD, PhD
Institut Gustave Roussy
University of Paris Saclay
Villejuif, France

June
3
Monday
6:15 PM CDT

OSA and Obesity

Cases in Practice: Prioritizing Weight Loss for People With Sleep Disorders and Overweight or Obesity

Houston, TX

Jaime Almandoz, MD, MBA, FTOS
University of Texas Southwestern Medical Center
Dallas, Texas

Safia Khan, MD
University of Texas Southwestern Medical Center
Dallas, Texas

June
13
Thursday
7:45 CEST

CLL

Opening With Innovation in Chronic Lymphocytic Leukemia (CLL): The Practicalities and Potential of Finite Therapy With Bruton Tyrosine Kinase Inhibitors (BTKi) Platforms

Madrid, Spain

Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
IRCCS Ospedale San Raffaele
Milano, Italy

June
15
Saturday
17:45 CEST

MANTLE CELL LYMPHOMA

Stepping Forward to Transform Mantle Cell Lymphoma (MCL) Management: Guidance on the Selection and Use of Bruton Tyrosine Kinase Inhibitors (BTKi) as First-Line Therapy

Madrid, Spain

Pier Luigi Zinzani, MD, PhD
Institute of Hematology "Seràgnoli"
University of Bologna
Bologna, Italy